ORMP insider receives 209,291 shares in stock awards

By AlphaYouPublished Sep 25, 2026Form 4

Stocks in this disclosure

Reported activity

Gabay Avraham

Reporting filer

Gabay Avraham reported 209,291 shares of Common Stock in ORAMED PHARMACEUTICALS INC. as grants or awards dated 2026-09-24. The Form 4 was disclosed on Sep 25, 2026. These were stock awards, not open-market purchases.

Disclosed: Sep 25, 2026

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Common Stock	Gabay Avraham	2026-09-24	A	Grant or award	209291	Not stated (see footnotes)	881,076	1 day	Filed terms security Title: Common Stock transaction Date: 2026-09-24 deemed Execution Date: transaction Form Type: 4 transaction Code: A equity Swap Involved: 0 transaction Timeliness: transaction Shares: 209291 id: F1 transaction Acquired Disposed Code: A shares Owned Following Transaction: 881076 direct Or Indirect Ownership: D

Common Stock

Owner: Gabay Avraham
Date: 2026-09-24
Code: A
Action: Grant or award
Quantity: 209291
Price: Not stated (see footnotes)
Following holdings: 881,076
Reporting delay: 1 day
Filed terms and references: Filed terms
security Title: Common Stock
transaction Date: 2026-09-24
deemed Execution Date:
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 209291
id: F1
transaction Acquired Disposed Code: A
shares Owned Following Transaction: 881076
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
Gabay Avraham: Chief Financial Officer.
F1: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.

Original sources

SEC ownership filing

Prepared automatically from public filing data. Report a correction.

Security

Owner

Date

Code

Action

Quantity

Price

Following holdings

Reporting delay

Filed terms and references

Common Stock

Gabay Avraham

2026-09-24

Grant or award

209291

Not stated (see footnotes)

881,076

1 day

Filed terms

security Title: Common Stock
transaction Date: 2026-09-24
deemed Execution Date:
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 209291
id: F1
transaction Acquired Disposed Code: A
shares Owned Following Transaction: 881076
direct Or Indirect Ownership: D

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.

Gabay Avraham: Chief Financial Officer.

F1: On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.